Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-696-3 | CAS number: 98-73-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
LD50 oral, Swiss inbred white mice tested by intragastic administration, 10 mice per dose, doses of 350, 400, 550, 600, 650, 700, and 800 mg/kg bw: 568 mg/kg bw (Federal Institute for Occupational Safety and Health, Division for Chemicals and Biocides Regulation, Germany (2009); Shell Development Company (1950))
LD50 dermal, New Zealand White rabbits, percutaneous administration, single dose, 30% PTBBA solution in DMSO (w/v): > 900 mg/kg bw;
LD50 dermal: The acute single dose percutaneous LD50 value of PTBBA (no data on purity) as a 30% solution in DMSO (w/v) was found to be approximately 300 mg/kg in Carworth Farm E strain (CFE) rats in a study using 2 males and 2 females each at dose levels of 75, 150, 300, and 900 mg/kg bw. (Federal Institute for Occupational Safety and Health, Division for Chemicals and Biocides Regulation, Germany (2009)), Shell Research Ltd. London (1975))
LC50 inhalation, groups of 6 male and 6 female Fischer rats exposed to PTBBA dust at doses of 0.0, 0.495 , 0.668, 0.958 or 1.802 mg/l for 4 hours (MMAD in the range of 4.0-5.5 micrometer: > 1.802 mg/kg. (Federal Institute for Occupational Safety and Health, Division for Chemicals and Biocides Regulation, Germany (2009), Darmer et al. (1982, 1984), Lu et al. (1987))
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: data contained in EU risk assessment report of the substance - credibility is assumed. Reference to origin (Shell Development Company)
- Principles of method if other than guideline:
- Determination of oral LD 50 of the test substance by intragastical administration of different concentrations in an aqueous suspension of gum acacia.
- GLP compliance:
- not specified
- Species:
- mouse
- Strain:
- other: Swiss inbred
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- white mice
- Route of administration:
- other: intragastic
- Vehicle:
- other: gum acacia in water
- Details on oral exposure:
- administration of an aqueous suspension of the test substance in gum acacia
- Doses:
- 350, 400, 550, 600, 650, 700, and 800 mg/kg bw
- No. of animals per sex per dose:
- 10
- Dose descriptor:
- LD50
- Effect level:
- 568 mg/kg bw
Reference
Doses of 350, 400, 550, 600, 650, 700, and 800 mg/kg bw were given to 10 mice each resulting in the following mortalities: after administration of 350 mg/kg 1/10 mice died on day 2; after administration of 400 mg/kg 4/10, after 550, 600, and 650 mg/kg 5/10 each, after 700 mg/kg 7/10, and after 800 mg/kg all mice died within 24 hours. The mice were mildly depressed within 1/3 hours after dosing. Within an hour, signs of muscular distress, marked incoordination and the Straub tail effect (spinal cord excitant) were present. At 5 hours a paralysis of the forelegs was evident in two thirds of the mice. In 3 of these, response of the tail and paws to painful stimuli was depressed or absent, but recovery occasionally followed even this deep depression. The pathologic changes noted in the 22 mice autopsied included signs off lung irritation, hemorrhage of the lungs, increased pigmentation of the liver, denuding of the epithelium of the intestines, and hyperemia of the intestines.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 568 mg/kg bw
- Quality of whole database:
- reliable reference
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: data contained in EU risk assessment report of the substance - credibility is assumed. (In the EU report it is referred to the original study of Darmer et al.(1982, 1984) and Lu et al. (1987))
- Principles of method if other than guideline:
- Exposition of rats to dust of PTBBA. Determination of acute inhalation toxicity (LC50).
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- other: Fischer
- Sex:
- male/female
- Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- not specified
- Vehicle:
- not specified
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 1.802 mg/L air
- Conclusions:
- According to the cited results the test substance provided as dust to male and female rats has a LC50 at greater than 1.802 mg dust/L.
Reference
At the highest concentration of 1.802 mg/l 2/6 males and 1/6 females died. This indicates that the LC50 is > 1.802 mg dust/l. However, other major toxicological effects were seen at all concentrations tested and a No-Effect-Level for a single four hour exposure could not be determined. At the lowest concentration of 0.495 mg/l effects on testes, in spinal cord and on rate of body weight gain were noted. Testicular effects were characterised among others by decreased sperm counts and microscopic lesions including reduction of tubular multinucleated cells. The forelimb neuropathy was described microscopically as multifocal poliomyelopathy. Decreased rate of body weight gain was observed in both sexes on days 4 and 14 exposed to all dose levels of PTBBA
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 1.8 mg/m³ air
- Quality of whole database:
- reliable reference
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: data contained in EU risk assessment report of the substance - credibility is assumed. Reference to origin (Shell Research Ltd. London)
- Principles of method if other than guideline:
- Dermal acute toxicity (LD50) of the test substance determined using rats and rabbits, application percutaneous in DMSO solution or as dry powder
- GLP compliance:
- not specified
- Conclusions:
- According to the cited results the LD50 (percutaneous) of the test substance has been determined to be approximately 300 mg/kg in male and female Carworth Farm E strain (CFE) rats.
Reference
The acute single dose percutaneous LD50 value of PTBBA (no data on purity) as a 30% solution in DMSO (w/v) was found to be approximately 300 mg/kg in Carworth Farm E strain (CFE) rats in a study using 2 males and 2 females each at dose levels of 75, 150, 300, and 900 mg/kg bw. After application of 75 mg/kg none of the rats died, after application of 150 mg/kg 0/2 males and 1/2 females died on day 2, after application of 300 mg/kg 2/2 males and 0/2 females died within 4 days, after application of 900 mg/kg all rats died within 4 days. No further information is given (Shell Research Ltd. London, unpublished report 1975).
In studies with New Zealand White rabbits, however, a dermal LD50 value of > 900 mg/kg bw for a 30% solution in DMSO (w/v), and of > 2000 mg/kg bw for the dry powder were determined. The acute single dose percutaneous LD50 value of 4-tert- butylbenzoic acid (no data on purity) as a 30% w/v solution in DMSO was found to be greater than 900 mg/kg, the maximum volume of the most concentrated solution that could be used. The LD50 value of the dry powder was found to be greater than 2000 mg/kg in rabbits. No pathological lesions were found in the tissues of the rabbits exposed to the powdered substance. No further information is given (Shell Research Ltd. London, unpublished report 1975).
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 300 mg/kg bw
- Quality of whole database:
- reliable reference
Additional information
EU risk assessment report of 2009, p.52: 4.1.2.2.3 Summary of acute toxicity, 4.1.2.3 Human data on acute toxicity of 4 -tert-butylbenzoic acid are not available. In studies with rats, oral LD50 values of > 550 mg/kg and < 800 mg/kg bw were detected with females being slightly more sensitive than males (Hunter et al., 1965; Procter & Gamble Comp. 1986; Shell Comp. 1950). Testicular atrophy was produced in male rats exposed to a single dose of 500 mg/kg, and degeneration of the generative cells in the seminiferous tubules was observed. The ovaries of surviving female rats were of normal appearance and presented no histological evidence of abnormal oogenesis (Hunter et al., 1965). The oral LD50 for mice was determined at 568 mg/kg bw (Shell Comp. 1950). An inhalation LC50 was not determined but exposure of rats to 1.802 mg dust/l/4 hours resulted in death in 2/6 male and 1/6 female rats. This indicates an LC 50 of > 1.8 mg/l. In these experiments testicular and CNS changes and changes in body weight were noted at the lowest concentration tested at 0.495 mg/l (Darmer et al., 1982; Darmer et al., 1984; Lu et al., 1987). The assessment of acute dermal toxicity is difficult, because the available data demonstrated great species differences (Shell Research Ltd. London, unpublished report 1975). In rats, a dermal LD50 of approximately 300 mg/kg resulted when a 30% substance solution in DMSO was tested. In rabbits the dermal LD50 was found to be > 2000 mg/kg when the dry powder was applied.
Justification for selection of acute toxicity – oral endpoint
Basis for the classification and labelling of the Risk Assessment Committee (ECHA/RAC/CLH-O-0000001579-64-01/A1, Adopted 21 February 2011) as acute tox. 4- H302.
Justification for selection of acute toxicity – inhalation endpoint
Summary of data cited in reliable reference (European Union Risk Assessment Report - 4-TERT-BUTYLBENZOIC ACID- RISK ASSESSMENT
July 2009, FINAL APPROVED VERSION)
Justification for selection of acute toxicity – dermal endpoint
Summary of data cited in reliable reference (European Union Risk Assessment Report - 4-TERT-BUTYLBENZOIC ACID- RISK ASSESSMENT
July 2009, FINAL APPROVED VERSION)
Justification for classification or non-classification
EU risk assessment report of 2009, p.52:
Based on the above data, 4-tert-butylbenzoic acid is to be classified "Xn, harmful" and labelled with "R 22, Harmful if swallowed". The TC C&L in September 2007 agreed that for acute toxicity the available LC50 for inhalation and the LD50 for dermal application were not sufficient for classification. Committee for Risk Assessment RAC Adopted 21 February 2011, p. 5: Based on the data above, the test substance 4 -tert-butylbenzoic acid has been classified according to EC No. 1272/2008 as "Acute Tox. 4 - H302 - Harmful if swallowed.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
